Targeting SARS-CoV-2-platelet interactions in COVID-19 and vaccine-related thrombosis.
journal contributionposted on 2021-08-04, 10:41 authored by Dermot CoxDermot Cox
It is clear that COVID-19 is more than a pneumonia and is associated with a coagulopathy and multi-organ failure. While the use of anti-coagulants does reduce the incidence of pulmonary emboli, it does not help with survival. This suggests that the coagulopathy is more likely to be platelet-driven rather than thrombin-driven. There is significant evidence to suggest that SARS-CoV-2 virions directly interact with platelets to trigger activation leading to thrombocytopenia and thrombosis. I propose a model of multiple interactions between SARS-CoV-2 and platelets that has many similarities to that with Staphylococcus aureus and Dengue virus. As platelet activation and thrombosis are major factors in poor prognosis, therapeutics that target the platelet-SARS-CoV-2 interaction have potential in treating COVID-19 and other virus infections.
CommentsThe original article is available at https://www.frontiersin.org
Published CitationCox D. Targeting SARS-CoV-2-platelet interactions in COVID-19 and vaccine-related thrombosis. Front Pharmacol. 2021;12:708665.
Publication Date5 July 2021
- School of Pharmacy and Biomolecular Sciences
- Immunity, Infection and Inflammation
- Vascular Biology
PublisherFrontiers Media SA
- Published Version (Version of Record)
Pharmacology and Pharmaceutical SciencesFcgamma receptor IIASARS-CoV-2bacteriaimmunothrombosisplateletssepsisvaccine thrombosisVirusPandemicsCoronavirusVaccine-Related ThrombosisCOVID-19SARS-CoV-2-Associated IllnessesTargeting PlateletsInfectious DiseasesPharmaceutical SciencesRespiratory DiseasesCardiology (incl. Cardiovascular Diseases)